Vanrafia Approval Plays Into Novartis’s Multipronged IgAN Approach

Atrasentan Joins Iptacopan On The Market

The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.

Although Novartis’s immunoglobulin A nephropathy (IgAN) franchise will face considerable competition from other firms, the accelerated approval in the US of Vanrafia (atrasentan) further solidifies its market position by helping it to cover multiple stages of the pathogenesis of IgAN.

Key Takeaways

The FDA gave accelerated approval to Novartis’s Vanrafia for IgA nephropathy, making it the second drug in the company’s portfolio for the disease, after Fabhalta.
The company is taking a multipronged approach to IgAN, with Vanrafia, Fabhalta and the Phase III zigakibart targeting different parts of the disease pathogenesis

The US Food and Drug Administration approved Vanrafia for proteinuria reduction in primary IgAN on 2 April, making it the second Novartis drug marketed for the condition, coming after Fabhalta (iptacopan), which gained the same accelerated clearance in August

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: US FDA Delay Sends Biohaven Shares Down

16 May 2025

• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

13 May 2025

• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

12 May 2025

• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

09 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.